Johnson & Johnson

Johnson & Johnson

Global healthcare company offering pharma, devices.

Project Delivery Digital Engineering & Property Services Co-op

Year-roundPosted on 9/22/2026Deadline 10/11/26
$23.50 - $52.50/hr

+ Pension

Internship
Bachelor's, Master's
New Brunswick, NJ, USA
Hybrid

Hybrid work arrangement in New Brunswick, New Jersey.

No H1B Sponsorship

About the job

Requirements
  • Completion of undergraduate freshman year at an accredited university.
  • Currently pursuing a Bachelor's or Master's degree in Computer Science, Data & Analytics, Industrial Engineering, Artificial Intelligence, or a related field.
  • A cumulative GPA of 3.0 or higher across all college coursework.
  • No summer internship contract or other employment commitment that interferes with the specified contract dates.
  • Experience in computer science or engineering roles focused on artificial intelligence, generative artificial intelligence, cloud computing, and automation.
  • Experience with software development and software engineering.
  • Understanding of cloud platforms such as Amazon Web Services, Microsoft Azure, or Google Cloud.
  • Understanding of machine learning algorithms, neural networks, and artificial intelligence frameworks.
  • Understanding of full-stack development, including front-end and back-end technologies such as JavaScript, Node.js, React, Angular, Python, Java, C#, C++, HTML/CSS, Git, and continuous integration/continuous delivery.
  • Experience with web design and maintenance, including SharePoint Modern, Figma, React, TypeScript, and HTML/CSS.
  • Experience with database design and management, including SQL and NoSQL.
  • Experience developing dashboards such as Power BI dashboards.
  • Experience with data structures such as stacks, linked lists, trees, and graphs.
  • Familiarity with application programming interface development and utilization.
  • Strong communication and interpersonal skills to work effectively in a collaborative team environment.
  • Problem-solving skills and the ability to think strategically.
  • Analytical mindset and eagerness to learn new technologies and methodologies.
  • Permanent authorization to work in the United States without requiring employment visa sponsorship now or in the future.
Responsibilities
  • Work with the BIM subject matter expert, data scientists, software engineers, and other partners to define technical requirements and specifications for Digital Engineering applications.
  • Support the design, development, and implementation of data libraries, search capabilities, user interfaces, and cloud solutions for Digital Engineering applications.
  • Collect, transform, and analyze data and create dashboards for Digital Engineering initiatives.
  • Use application programming interfaces to access and analyze data across different systems.
  • Manage updates to the Digital Engineering website, including process flows, dashboards, and training videos.
  • Assess and share advancements in artificial intelligence, cloud computing, and automation and apply this knowledge to enhance product offerings.
  • Analyze technology performance metrics and user feedback to drive continuous improvement.
  • Support development of performance management reports, including Power BI dashboards, in alignment with Process Excellence team requirements.
  • Implement and maintain online environments supporting onboarding, orientation, and ongoing training activities.
  • Prepare and present project progress reports and presentations as required.
  • Organize, attend, and participate in team, stakeholder, and business partner meetings.
  • Coordinate and maintain SharePoint and Microsoft Teams documents.
  • Support the team with ad hoc requests.
  • Support and participate in team and Credo activities.
Desired Qualifications
  • Familiarity with the healthcare industry.
  • Experience building relationships with internal and external project partners and working in team environments.
  • Customer service experience.
  • Ability to hold oneself and team members accountable for meeting project milestones and completing tasks.

About the company

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Second-quarter 2026 sales rose 6.6% to $25.3 billion, with raised full-year guidance.
  • TREMFYA posted $2 billion quarterly sales in July 2026, growing 72.5%.
  • CAPLYTA met its bipolar mania primary endpoint on September 21, 2026.

What critics are saying

  • Talc litigation still threatens cash flow after the $5.5 billion settlement announced July 2026.
  • Apollo's orthopedics talks signal DePuy Synthes weakness and forced portfolio shrinkage.
  • AbbVie's etentamig and biosimilars pressure CARVYKTI, TREMFYA, and post-STELARA growth.

What makes Johnson & Johnson unique

  • J&J has 28 billion-dollar products, reducing dependence on any single franchise.
  • TREMFYA and DARZALEX offset STELARA erosion, proving resilient portfolio management.
  • CAPLYTA, CARVYKTI, and RYBREVANT deepen leadership across psychiatry, cell therapy, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-3%
Yahoo Finance
Sep 18th, 2026
J&J stock trades at 28x earnings, but STELARA biosimilar hit distorts valuation

Johnson & Johnson stock has surged 57% over the past year, outpacing the S&P 500's 17% return. Trading at approximately $270 per share, the stock appears expensive at 28.3 times trailing earnings. However, those trailing figures include STELARA, which lost market share to biosimilar competition and reduced operational sales growth by 460 basis points in Q2 2026. Excluding STELARA, the company achieved double-digit growth. The forward outlook looks more attractive, with the stock trading at 24.1 times fiscal 2026 earnings and 20.9 times 2027 estimates. Johnson & Johnson's portfolio includes 28 products generating over $1 billion annually each, with trailing twelve-month revenue near $98 billion. Meanwhile, TREMFYA grew 71% in Q2 2026, becoming the fastest-growing advanced therapy in Crohn's disease and ulcerative colitis. Operating margins improved to 26.8% from a three-year average of 25.7%, supporting expectations for continued margin expansion.

Yahoo Finance
Sep 14th, 2026
Apollo in talks to acquire J&J's orthopedics unit for $20B

Johnson & Johnson shares rose 1.3% in pre-market trading following reports that Apollo Global Management is in discussions to acquire its orthopedics business for approximately $20 billion. Bloomberg News reported the potential deal could be finalised within weeks, citing people familiar with the matter. The orthopedics division generated $9.3 billion in revenue in 2025. However, the business has faced thousands of lawsuits related to its hip replacement devices. No transaction has been confirmed. Investors responded positively to news of the reported discussions and the potential valuation of the orthopedics unit.

Yahoo Finance
Sep 3rd, 2026
J&J rises 1% as AbbVie's myeloma drug shows 74% response rate

Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.

Yahoo Finance
Sep 1st, 2026
P&G commits $10B in dividends amid 2.8B productivity savings while J&J's 28.5% stock surge masks mid-2027 spinoff risk

Procter & Gamble's dividend strategy is outpacing Johnson & Johnson's despite J&J's stronger stock performance this year. J&J's forward annualised dividend of $5.36 exceeds P&G's $4.354, but its planned mid-2027 DePuy Synthes spinoff threatens its dividend streak. P&G CEO Shailesh Jejurikar committed $10 billion in dividends and $5 billion in buybacks for fiscal 2027, supported by $2.8 billion in productivity savings. The company returned over $15 billion to shareholders in fiscal 2026, including more than $10 billion in dividends. J&J's stock surged 28.5% year-to-date versus P&G's 1.3% gain, driven by strong product performance. However, the upcoming spinoff poses uncertainty, as similar corporate events have disrupted other companies' dividend streaks. P&G faces no such structural risk.

Yahoo Finance
Aug 29th, 2026
J&J stock surges 52.8% in a year, outpacing consumer staples sector with strong pharma growth

Johnson & Johnson has significantly outperformed the consumer staples sector, with shares rising 52.8% over the past 52 weeks compared to the State Street Consumer Staples Select Sector SPDR Fund's 6.5% gain. The New Brunswick-based healthcare giant, valued at $640.5 billion, has seen particularly strong momentum recently, climbing 16.1% over three months. The company's strong performance follows solid second-quarter results released on 15 July, where sales increased 6.6% year-over-year to $25.31 billion. Adjusted earnings per share of $2.90 exceeded market expectations. Johnson & Johnson raised its full-year guidance, projecting adjusted EPS of $11.58 and sales of $101.1 billion. The stock currently trades just 3.1% below its 52-week high of $276.47, reached on 19 August.